The Chasm We Must Cross in Japan for Re-promotion of the HPV Vaccine

Ueda, Yutaka; Katayama, Kazuhisa; Yagi, Akira; Kimura, Tadashi

doi:10.1158/1940-6207.capr-21-0091

Cited by 8 publications

(6 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently, the HPV vaccine continues to have a strong negative image in Japan. 44,45 In Japan, the incidence of cervical cancer is rapidly increasing among young female individuals, and its prevention using adequate HPV vaccination is crucial. 46 We proposed various vaccination coverage dissemination strategies to restore HPV vaccination coverage as soon as possible.…”

Section: Discussionmentioning

confidence: 99%

Human Papillomavirus Vaccination by Birth Fiscal Year in Japan

Yagi,

Ueda,

Oka

et al. 2024

JAMA Netw Open

Self Cite

View full text Add to dashboard Cite

ImportanceThe Ministry of Health, Labour, and Welfare (MHLW) of Japan aggregates human papillomavirus (HPV) vaccination data across Japan for each fiscal year (FY) by age at vaccination. Birth FY (BFY)–specific vaccination coverage remains unknown.ObjectiveTo calculate the BFY-specific vaccination coverage for each FY and the cumulative first-dose coverage for each BFY in Japan, to understand the generation-specific vaccination coverage, and to estimate the cumulative first-dose coverage of each BFY that would be achieved by FY 2028 vs World Health Organization (WHO) targets.Design, Setting, and ParticipantsIn this cross-sectional study, MHLW-published national age-specific HPV vaccination numbers and demographic data for female individuals were used to calculate the BFY-specific first-dose coverage for each FY and the BFY-specific cumulative first-dose coverage. It was assumed that the BFYs 2007 to 2012 vaccination coverage in FY 2023 to 2028 would remain the same as the vaccination coverage of the same grade in FY 2022 to estimate the cumulative first-dose coverage that would be achieved by FY 2028. Data analysis was performed from December 2023 to January 2024.ExposureTwo MHLW policy changes were the government’s suspension of proactive recommendation for HPV vaccination in June 2013 and the government’s resumption of proactive recommendation for HPV vaccination in April 2022.Main Outcomes and MeasuresThe primary outcome was generation-specific vaccination coverage among female individuals born in BFYs 1994 to 2010 in FYs 2010 to 2022, calculated using reconfigured published data.ResultsIn this study of vaccination data for 9 414 620 female individuals, the generation-specific vaccination coverage was 71.96% for the vaccination generation (BFYs 1994-1999), 4.62% for the vaccine-suspension generation (BFYs 2000-2003), 16.16% for the generation that received information individually (BFYs 2004-2009), and 2.83% for the vaccine-resumed generation (BFY 2010). HPV routine vaccination coverage was extremely low in BFYs 2000 to 2010 (0.84%-25.21%) vs BFYs 1994 to 1999 (53.31%-79.47%). The cumulative first-dose coverage that was estimated to be achieved in the vaccine-resumed generation by FY 2028 plateaued at 43.16%.Conclusions and RelevanceEven after the resumption of MHLW’s proactive recommendations, HPV vaccination coverage has only minimally recovered in Japan. The cumulative first-dose coverage that was estimated to be achieved in the vaccine-resumed generation by FY 2028 is below the WHO target. These findings reveal that stronger cervical cancer control measures are required, particularly for the vaccine-resumed generation, which will plateau at approximately one-half the WHO target values.

show abstract

Section: Discussionmentioning

confidence: 99%

Human Papillomavirus Vaccination by Birth Fiscal Year in Japan

Yagi,

Ueda,

Oka

et al. 2024

JAMA Netw Open

Self Cite

View full text Add to dashboard Cite

show abstract

“…In October of 2020, the MHLW revised its public information leaflet for the HPV vaccine, and they advised all local governments of the proven effectiveness of providing an individual notification to girls in the targeted age-range [ 24 ]. In Japan, we have now shown that positive peer education is going to be essential to overcome the cascade of negative social pressures that have accumulated against HPV vaccination [ 25 ].…”

Section: Discussionmentioning

confidence: 99%

The ‘best friend effect’: a promising tool to encourage HPV vaccination in Japan

Yagi

Ueda

Tomine³

et al. 2022

Int J Clin Oncol

Self Cite

View full text Add to dashboard Cite

Background In Japan, HPV vaccination rates has dramaticaly declined since 2013. Since mothers are the ones making the decision to vaccinate their daughters against HPV, we probed the mothers’ intention to receive vaccinations for themselves and to vaccinate their daughters against HPV, and their reasoning. Methods An internet survey was conducted in March of 2021. Through the screening, 1576 participants were extracted from a survey panel and divided into 3 groups based on their daughter’s birth fiscal year (Group 1: 1994 to 1999, Group 2: 2000 to 2003, Group3: 2004 to 2008). The chi-square test and residual analysis were used for the statistical analysis of comparison among the groups. Logistic regression analysis was used to identify independent variables with mothers intention to get their daughters vaccinated under specific situations. Results The percentage of respondents without anxiety regarding their daughter’s general vaccination was significantly higher in Group 1 ( p < 0.05). In the mothers of daughters born in or after 2000 when vaccination rates declined (Groups 2 and 3), a situation in which ‘The daughter's best friends were vaccinated before her’ made the mothers think positively about HPV vaccination, and to the same degree as a situation in which ‘You received a notice from your local government recommending vaccination’ (Group 2: 41.6% (214/514) and 40.5% (208/514), Group 3: 48.5% (257/530) and 47.0% (249/530)). Conclusion If mothers who have had their daughters vaccinated were to recommend HPV vaccination to their close friends, ‘the best friend effect’ should promote others to be vaccinated. Supplementary Information The online version contains supplementary material available at 10.1007/s10147-022-02240-7.

show abstract

“…From this, they recognized that successful interventions would need to start with recruiting early adopters, instead of persons later in the diffusion cycle (Rosen & Goodson, 2014). In Japan, DOI has been used to explore phases of public health education campaigns to move between each stage of the diffusion cycle (Ueda, Katayama, Yagi, & Kimura, 2021). DOI has also been suggested as a model for understanding and exploring healthcare policies generally (Dearing & Cox, 2018), and more recently has been used to evaluate intention to receive COVID-19 vaccination in China (Mo et al, 2021).…”

Section: Diffusion Of Innovationmentioning

confidence: 99%

Skeptical Health Mavens May Limit COVID-19 Vaccine Diffusion: Using the Innovation Diffusion Cycle to Interpret Results of a Cross-sectional Survey among People Who are Socially Vulnerable

Smith

Bone

Visco

et al. 2022

Journal of Health Communication

View full text Add to dashboard Cite

We sought to identify barriers to COVID-19 vaccine uptake among persons who are socially vulnerable in light of the natural cycle of innovation diffusion. Widespread adoption of a health innovation requires a cadre of opinion leaders to build on successes experienced by early adopters. One type of opinion leader in healthcare are health mavens: members of a community who maintain up-to-date health knowledge and share their knowledge others. We surveyed 139 persons who are socially vulnerable regarding their COVID-19 vaccination intention, and evaluated their responses based on psychological traits captured by two scales: innovativeness and health mavenism. Health mavenism was not strongly correlated with COVID-19 vaccine intention. Health mavens often relied on their own healthcare providers (n = 46) and health agency websites (n = 42) for vaccine information. Those who relied on their faith leaders (n = 4) reported a lower likelihood of getting vaccinated (31.5% vs. 76.0%, p < .05). The observed lack of support by health mavens represents a critical barrier to COVID-19 vaccine uptake; targeting campaigns to health mavens may increase COVID-19 vaccine uptake in socially vulnerable communities.

show abstract

The Chasm We Must Cross in Japan for Re-promotion of the HPV Vaccine

Cited by 8 publications

References 21 publications

Human Papillomavirus Vaccination by Birth Fiscal Year in Japan

Human Papillomavirus Vaccination by Birth Fiscal Year in Japan

The ‘best friend effect’: a promising tool to encourage HPV vaccination in Japan

Skeptical Health Mavens May Limit COVID-19 Vaccine Diffusion: Using the Innovation Diffusion Cycle to Interpret Results of a Cross-sectional Survey among People Who are Socially Vulnerable

Contact Info

Product

Resources

About